Private Advisor Group, LLC Bio N Tech Se Transaction History

Private Advisor Group, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	BUY	$122.57 - $153.67 $242,933 - $304,573	1,982 New	1,982 $246,000
Q3 2022 Oct 14, 2022	SELL	$127.65 - $183.11 $40,209 - $57,679	-315 Reduced 4.43%	6,802 $917,000
Q2 2022 Jul 13, 2022	SELL	$123.25 - $186.24 $281,626 - $425,558	-2,285 Reduced 24.3%	7,117 $1.06 Million
Q1 2022 May 12, 2022	SELL	$126.25 - $231.85 $318,907 - $585,653	-2,526 Reduced 21.18%	9,402 $1.6 Million
Q4 2021 Feb 10, 2022	SELL	$216.64 - $362.52 $498,921 - $834,883	-2,303 Reduced 16.18%	11,928 $3.08 Million
Q3 2021 Oct 14, 2021	BUY	$205.93 - $447.23 $260,089 - $564,851	1,263 Added 9.74%	14,231 $3.89 Million
Q2 2021 Aug 12, 2021	BUY	$113.32 - $241.49 $226 - $482	2 Added 0.02%	12,968 $2.9 Million
Q1 2021 Apr 22, 2021	SELL	$85.73 - $119.5 $409,360 - $570,612	-4,775 Reduced 26.92%	12,966 $1.42 Million
Q4 2020 Apr 01, 2021	BUY	$72.71 - $129.54 $699,542 - $1.25 Million	9,621 Added 118.49%	17,741 $1.45 Million
Q3 2020 Nov 02, 2020	BUY	$57.81 - $104.17 $324,892 - $585,435	5,620 Added 224.8%	8,120 $562,000
Q2 2020 Aug 17, 2020	BUY	$38.58 - $66.74 $96,450 - $166,850	2,500 New	2,500 $167,000

357

38.3M

2.45M

2.29M

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $27.4B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

Get notified when there are updates to the investment portfolio of Private Advisor Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Private Advisor Group, LLC with notifications on news.